131 related articles for article (PubMed ID: 3521784)
1. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five-year follow-up.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Taylor RH; Stoodley B; Ellis H; Wastell C
Br J Surg; 1986 Jun; 73(6):446-50. PubMed ID: 3521784
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
[TBL] [Abstract][Full Text] [Related]
3. Effect of razoxane on metastases from colorectal cancer.
Hellmann K; Gilbert J; Evans M; Cassell P; Taylor R
Clin Exp Metastasis; 1987; 5(1):3-8. PubMed ID: 3829494
[TBL] [Abstract][Full Text] [Related]
4. A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Gilbert JM; Cassell PC; Ellis H; Wastell C; Hellmann K; Evans MG; Stoodley BJ
Recent Results Cancer Res; 1981; 79():48-58. PubMed ID: 7029684
[TBL] [Abstract][Full Text] [Related]
5. Prospective serial liver ultrasound scanning in resectable colorectal cancer treated with adjuvant razoxane.
Taylor RH; Gilbert JM; Evans MG; Lane HG; Cassell PG
Clin Exp Metastasis; 1984; 2(4):321-31. PubMed ID: 6399698
[TBL] [Abstract][Full Text] [Related]
6. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of experimental colorectal cancer by razoxane (ICRF-159).
Gilbert JM; Thompson EM; Slavin G; Kark AE
Br J Surg; 1984 Aug; 71(8):600-3. PubMed ID: 6743979
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer.
Slevin ML; Harvey VJ; Wrigley PF
Cancer Chemother Pharmacol; 1983; 10(3):228-9. PubMed ID: 6345019
[No Abstract] [Full Text] [Related]
9. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Vogl SE; Lanham R; Kaplan BH
Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
[No Abstract] [Full Text] [Related]
11. Razoxane, metastasis and adjuvant chemotherapy.
Hellmann K
Clin Exp Metastasis; 1987; 5(1):1-2. PubMed ID: 3829493
[No Abstract] [Full Text] [Related]
12. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
[No Abstract] [Full Text] [Related]
13. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
O'Connell MJ; Schutt AJ; Moertel CG; Rubin J; Hahn RG; Scott M
Am J Clin Oncol; 1987 Aug; 10(4):320-4. PubMed ID: 3303905
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
Vogl SE; Qazi R; Berenzweig M
Cancer Treat Rep; 1980; 64(10-11):1143-5. PubMed ID: 7459902
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
Paul AR; Catalano RB; Engstrom PF
Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time.
Hafström L; Rudenstam CM; Domellöf L
Br J Surg; 1985 Feb; 72(2):138-41. PubMed ID: 3882183
[TBL] [Abstract][Full Text] [Related]
17. Irradiation with and without razoxane in the treatment of incompletely resected or inoperable recurrent rectal cancer. Results of a small randomized multicenter study.
Rhomberg W; Hammer J; Sedlmayer F; Eiter H; Seewald D; Schneider B
Strahlenther Onkol; 2007 Jul; 183(7):380-4. PubMed ID: 17609871
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colo-rectal cancer. Report of a controlled randomised study of 603 patients.
Kingston RD; Fielding JW; Palmer MK
Int J Colorectal Dis; 1993 Jul; 8(2):106-10. PubMed ID: 8409683
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Engstrom PF; MacIntyre JM; Mittelman A; Klaassen DJ
Am J Clin Oncol; 1984 Aug; 7(4):313-8. PubMed ID: 6377866
[TBL] [Abstract][Full Text] [Related]
20. ICRF-159: current status and clinical prospects.
Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
[No Abstract] [Full Text] [Related]
[Next] [New Search]
